menu
    • menu
    [{"orgOrder":0,"company":"Swiss Pharma Nigeria","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NIGERIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Swiss Pharma Nigeria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Pharma Nigeria \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"6","companyTruncated":"Swiss Pharma Nigeria \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Emzor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NIGERIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emzor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emzor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emzor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Emzor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NIGERIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emzor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emzor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emzor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Kintampo Health Research Centre, Ghana","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana","highestDevelopmentStatusID":"1","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana"}]

    Find Clinical Drug Pipeline Developments & Deals for Sulfadoxine

    Menu

    Sulfadoxine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Swiss Pharma Nigeria

                            Nigeria arrow
                            FNCE
                            Not Confirmed

                            Swiss Pharma Nigeria

                            Nigeria arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet

                            Details : Sulfadoxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2024

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            FNCE
                            Not Confirmed

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Kintampo Health Research Centre, Ghana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control

                            Details : Sulphadoxine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 26, 2023

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Kintampo Health Research Centre, Ghana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Emzor Pharmaceutical

                            Country arrow
                            FNCE
                            Not Confirmed

                            Emzor Pharmaceutical

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Condi...

                            Details : Sulfadoxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 11, 2022

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Emzor Pharmaceutical

                            Country arrow
                            FNCE
                            Not Confirmed

                            Emzor Pharmaceutical

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Sulfadoxine/ Pyrimethamine Tablets in Healthy Subjects Under Fasting Conditions

                            Details : Sulfadoxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 08, 2020

                            Lead Product(s) : Sulfadoxine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth